Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-25T18:06:58.306Z Has data issue: false hasContentIssue false

Efectividad de la clozapina en un servicio psiquiátrico en Italia

Published online by Cambridge University Press:  12 May 2020

D. Berardi
Affiliation:
Universidad de Bolonia, Departamento de Psiquiatría, “P. Ottonello”, Viale C. Pepoli, 5, 40123, Bolonia
M. Troia
Affiliation:
Universidad de Bolonia, Departamento de Psiquiatría, “P. Ottonello”, Viale C. Pepoli, 5, 40123, Bolonia
M. Dell'Atti
Affiliation:
Universidad de Bolonia, Departamento de Psiquiatría, “P. Ottonello”, Viale C. Pepoli, 5, 40123, Bolonia
C. Bartoletti
Affiliation:
Servicio de Salud Mental “Villa Olimpia”, AUSL Bologna, Italia
C. Cantaroni
Affiliation:
Universidad de Bolonia, Departamento de Psiquiatría, “P. Ottonello”, Viale C. Pepoli, 5, 40123, Bolonia
G. Ferrari
Affiliation:
Universidad de Bolonia, Departamento de Psiquiatría, “P. Ottonello”, Viale C. Pepoli, 5, 40123, Bolonia
Get access

Resumen

Se administró clozapina a 28 esquizofrénicos resistentes al tratamiento en los servicios psiquiátricos en Bolonia. A las 26 semanas, el 62% de los pacientes mostraba respuesta. Los síntomas positivos y negativos mejoraron, pero la disminución de los síntomas negativos dependía en parte de la mejoría de los positivos y los extrapiramidales. No se vieron casos de agranulocitosis. Algunos abandonos estaban relacionados con dificultades con la mejoría psicopatológica.

Type
Comunicación breve
Copyright
Copyright © European Psychiatric Association 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Andreasen, NC.The scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa; 1983.Google Scholar
Andreasen, NC.The scale for the assessment of positive symptoms (SAPS). Iowa City: University of Iowa; 1984.Google Scholar
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ed. III, revised. Washington: American Psychiatric Association; 1987.Google Scholar
Baldessarini, RJFrankenburg, FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746–54.Google ScholarPubMed
Barnes, TRE.A rating scale for drug-induced akathisia. Br J Psychiatr 1989; 154: 672–6.CrossRefGoogle ScholarPubMed
Breier, ABuchanan, RWIrish, DCarpenter, WT.Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Comm Psychiatry 1993; 44:1145–9.Google ScholarPubMed
Breier, ABuchanan, RWKirkpatrick, BDavis, ORIrish, DSummerfelt, ACarpenter, WT.Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20–6.Google ScholarPubMed
Cohen, SChiles, JMcNaughton, A.Weight gain associated with clozapine. Am J Psychiatry 1990; 147: 503–4.Google ScholarPubMed
Gordon, BJMilke, DJ.Dose related response to clozapine in a state psychiatric hospital population: a naturalistic study. Psychiatr Q 1996; 67 suppl 1: 6574.CrossRefGoogle Scholar
Guy, W.EDCEU assessment manual for psychopharmacology. Washington DC.US DHEW; 1976. Publishing number ADM 76338; 217–22: 283–6.Google Scholar
Kane, JHonigfeld, GSinger, JMeltzer, H.Clozapine for the treatment resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96.CrossRefGoogle ScholarPubMed
Kirkegaard, AHammershoj, EOstergard, P.Evaluation of side effects due to clozapine in long-term treatment of psychosis. Drug Resource 1982; 33: 465–8.Google Scholar
Leadbetter, RShutty, MPavalonis, DVieweg, VHiggins, PDowns, M.Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149: 6872.Google ScholarPubMed
Lieberman, JASafferman, AZPollazk, SSzymaski, SJohns, CHoward, A, et al.Clinical effects of clozapine in chornic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 1744–52.Google Scholar
Meltzer, HYBastani, B, Young Kwon, KRamirez, LFBurnett, SSharpe, J.A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology 1989; 99 suppl 1: 6872.CrossRefGoogle Scholar
Meltzer, HYBurnett, SBastani, BRamirez, LF.Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Comm Psychiatry 1990; 41: 892–7.Google ScholarPubMed
Meltzer, HY.Dimensions of outcome with clozapine. Br J Psychiatry 1992; 160 suppl 17: 4653.CrossRefGoogle Scholar
Miller, DPerry, PJCadoret, RJAndreasen, NC.Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35: 815.CrossRefGoogle ScholarPubMed
Pickar, DOwen, RRLitman, REKonicki, EGutierrez, RRapaport, MH.Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49: 345–53.CrossRefGoogle ScholarPubMed
Overall, JEGorham, DR.The Brief Psychiatry Rating Scale. Psychological Report 1962; 10: 799812.CrossRefGoogle Scholar
Povlsen, UGNoring, UFog, RGerlach, J.Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985; 71: 176–85.CrossRefGoogle Scholar
Schooler, NRKane, JM.Research diagnosis for tardive diskinesia. Arch Gen Psychiatry 1982; 39: 486–7.Google Scholar
Simpson, GMAngus, JWS.A Rating Scale for Extrapyramidal Side Effects. Acta Psychiatr Scand 1970; 212 suppl 44: 1119.CrossRefGoogle Scholar
Umbricht, DSGPollack, SKane, JM.Clozapine and weight gain. J Clin Psychiatry 1994; 55 suppl B: 157–60.Google ScholarPubMed
Urdain, APMestre, NPMestre, PPAguirre, JFP.Clozapine in the treatment of schizophrenia. Euro J Psychiatry 1990; 4: 91–4.Google Scholar
Verhoeven, WMDoesburg, WHSnoej, RRutgers, AJMPVandongen, PHM.Efficacy of clozapine in treatment-resistant psychosis and neuroleptic sensitivity: results of Dutch open multicenter project. Euro Psychiatry 1992; 7: 7784.CrossRefGoogle Scholar